TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells.
• The physiological role of TRAIL and its receptor (TRAIL-R) in tumorigenesis remains unclear.
• Conflicting results exist regarding TRAIL's role in tumor growth and development.

Purpose of the Study:

• To investigate the role of TRAIL-R in all stages of squamous cell carcinoma development.
• To determine if TRAIL-R acts as a metastasis suppressor.
• To elucidate the mechanism by which TRAIL-R might inhibit metastasis.

Main Methods:

• Utilized a multistage mouse model of squamous cell carcinoma.
• Examined tumor development and metastasis in TRAIL-R-deficient mice.
• Assessed TRAIL sensitivity of adherent and detached skin carcinoma cells in vitro.
• Investigated the role of the ERK signaling pathway in TRAIL resistance.

Main Results:

• TRAIL-R deficiency did not affect benign papilloma formation or progression to squamous cell carcinoma.
• Metastasis to lymph nodes was significantly increased in TRAIL-R-deficient mice.
• Adherent TRAIL-R-expressing cells were TRAIL resistant but sensitized upon detachment via ERK pathway inactivation.

Conclusions:

• TRAIL-R functions as a metastasis suppressor, not affecting primary tumor growth.
• TRAIL-R inactivation enhances lymph node metastasis.
• Detachment-induced sensitization to TRAIL, mediated by ERK pathway inactivation, provides a mechanism for metastasis suppression.
• Targeting TRAIL receptors with agonists may reduce metastasis in cancer patients.